Moderna launches COVID booster campaignHollan, MikePatient Care (Online)
A new report accuses American drugmaker Moderna of prioritizing profits from COVID-19 vaccines by keeping poor countries waiting. The New York Times says the vaccine maker has sold most of its doses to wealthier nations. Only one million doses have gone to low-income countries...
The art of COVID-19 communication Call for global biodiversity agreementModerna said it is looking at whether a booster shot – either of its existing vaccine or of a new shot designed to protect against the South Africa variant – could be made available in future if evidence...
CAMBRIDGE (CBS) -- The FDA on Fridayauthorized Moderna and Pfizer's COVID vaccine booster shotsfor all adults 18 and older. A few hours later, CDC vaccine advisers voted unanimously to recommend allowing the booster shots for all, and CDC Director Rochelle Walensky endorsed the advisory committe...
Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial. mRNA-1273.214 stimulated almost twice the neutralising antibody lev
[4] Fierce Pharma: Moderna's new booster launch tripped up by production issues at Catalent plant: reports [5] Fierce Pharma: No more free COVID vaccines: US plots move to private market in 2023, setting up market clash between Pfizer and Moderna ...
[3] MODERNA: CREATES NEW EXECUTIVE COMMITTEE ROLE AHEAD OF NEW PRODUCT LAUNCHES [4] Fierce Pharma: Moderna's new booster launch tripped up by production issues at Catalent plant: reports [5] Fierce Pharma: No more free COVID vaccines: US plots move to private market in 2023, setting up ...
https://www.biospace.com/article/moderna-s-new-bivalent-booster-proves-more-effective-vs-covid-19/ https://www.biospace.com/article/releases/moderna-announces-clinical-update-on-bivalent-covid-19-booster-platform/?keywords=...
The new shots target the omicron BA.5 subvariant as well as the original strain of Covid that first emerged in China in late 2019. The FDA and CDC expect the new boosters to provide superior protection against infection and disease because they target the ...
During anAxios COVID-19 vaccine eventon May 19, both the CEO of Moderna and the CEO of Pfizer said that depending on the research being done on the efficacy and longevity of the vaccines, a booster shot could be needed between either eight to 12 months after the recipient’s initial...